ZA200803440B - Compounds for the treatment of metabolic disorders - Google Patents

Compounds for the treatment of metabolic disorders

Info

Publication number: ZA200803440B
Authority: ZA; South Africa
Prior art keywords: compounds; treatment; metabolic disorders; metabolic; disorders
Prior art date: 2005-11-09

Application number

ZA200803440A

Other languages

English (en)

Inventor

Romantsev Fedor Evgenievich

Sharma Shalini

Borstel Reid W Von

Stephen D Wolpe

Original Assignee

Wellstat Therapeutics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-09

Filing date

2008-04-18

Publication date

2009-03-25

2008-04-18 Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp

2009-03-25 Publication of ZA200803440B publication Critical patent/ZA200803440B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200803440A 2005-11-09 2008-04-18 Compounds for the treatment of metabolic disorders ZA200803440B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US73480305P	2005-11-09	2005-11-09

Publications (1)

Publication Number	Publication Date
ZA200803440B true ZA200803440B (en)	2009-03-25

Family

ID=38024089

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200803440A ZA200803440B (en)	2005-11-09	2008-04-18	Compounds for the treatment of metabolic disorders

Country Status (15)

Country	Link
US (1)	US8178675B2 (xx)
EP (1)	EP1948152B1 (xx)
JP (2)	JP5240927B2 (xx)
KR (1)	KR101344392B1 (xx)
CN (2)	CN102743368A (xx)
AU (1)	AU2006311266B2 (xx)
BR (1)	BRPI0618500A2 (xx)
CA (1)	CA2627363C (xx)
IL (1)	IL190920A (xx)
NO (1)	NO20081821L (xx)
NZ (1)	NZ568048A (xx)
RU (1)	RU2420276C2 (xx)
UA (1)	UA95613C2 (xx)
WO (1)	WO2007056771A2 (xx)
ZA (1)	ZA200803440B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2530235T3 (es) *	2003-02-13	2015-02-27	Wellstat Therapeutics Corporation	Compuestos para el tratamiento de trastornos metabólicos
WO2007092729A2 (en) *	2006-02-02	2007-08-16	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
CN101361968B (zh) *	2007-08-06	2011-08-03	健能隆医药技术（上海）有限公司	白介素-22在治疗脂肪肝中的应用
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5496913B2 (ja) *	2008-01-15	2014-05-21	ウェルスタットセラピューティクスコーポレイション	代謝異常の治療のための化合物
NZ587433A (en) *	2008-03-13	2012-12-21	Wellstat Therapeutics Corp	Compounds and method for reducing uric acid
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012033720A1 (en)	2010-09-08	2012-03-15	Wellstat Therapeutics Corporation	Benzoic acid compounds for reducing uric acid
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104623637A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	Il-22二聚体在制备静脉注射药物中的应用
CN109328069B (zh)	2016-04-15	2023-09-01	亿一生物医药开发(上海)有限公司	Il-22在治疗坏死性小肠结肠炎中的用途
US12527875B2 (en)	2020-02-19	2026-01-20	Evive Biotechnology (Shanghai) Ltd	Methods for treating graft versus host disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE667498A (xx)	1964-07-28	1965-11-16
CS175831B1 (xx)	1974-12-17	1977-05-31
EP0540165A1 (en)	1991-10-03	1993-05-05	Zeneca Limited	Alkanoic acid derivatives
AU749505B2 (en)	1997-10-27	2002-06-27	Dr. Reddy's Laboratories Limited	Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en)	1997-10-27	1999-04-22	Dr. Reddy's Research Foundation	Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
DE60135742D1 (de) *	2000-05-29	2008-10-23	Kyorin Seiyaku Kk	Substituierte phenylpropionsäure-derivate
US7049342B2 (en) *	2000-05-29	2006-05-23	Kyorin Pharmaceutical Co., Ltd.	Substituted phenylpropionic acid derivatives
US6531494B1 (en)	2001-08-29	2003-03-11	Pharmacia Corporation	Gem-substituted αvβ3 antagonists
WO2002083616A1 (en)	2001-04-10	2002-10-24	Sankyo Company, Limited	α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE
IL159320A0 (en)	2001-06-12	2004-06-01	Wellstat Therapeutics Corp	Compounds for the treatment of metabolic disorders
JP2004123643A (ja)	2002-10-04	2004-04-22	Sankyo Co Ltd	ω−アリール−α−置換脂肪酸誘導体を含有する糖尿病予防剤、治療剤
CA2502297C (en)	2002-11-01	2011-12-13	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
ES2530235T3 (es) *	2003-02-13	2015-02-27	Wellstat Therapeutics Corporation	Compuestos para el tratamiento de trastornos metabólicos
DE602004030004D1 (de)	2003-04-15	2010-12-23	Wellstat Therapeutics Corp	Verbindungen zur behandlung von stoffwechselstörungen
US7361686B2 (en)	2003-04-22	2008-04-22	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
KR101192272B1 (ko)	2003-04-30	2012-10-17	웰스태트 테러퓨틱스 코포레이션	대사 질환의 치료용 화합물
UA88772C2 (ru)	2003-08-20	2009-11-25	Уэллстат Терепьютикс Корпорейшн	Соединения для лечения расстройств метаболизма
CA2536089A1 (en)	2003-08-20	2005-03-03	Eli Lilly And Company	Ppar modulators
US7816367B2 (en) *	2004-02-27	2010-10-19	Amgen Inc.	Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders

2006
- 2006-09-11 UA UAA200804957A patent/UA95613C2/ru unknown
- 2006-11-09 WO PCT/US2006/060727 patent/WO2007056771A2/en not_active Ceased
- 2006-11-09 CN CN2012102251310A patent/CN102743368A/zh active Pending
- 2006-11-09 AU AU2006311266A patent/AU2006311266B2/en not_active Ceased
- 2006-11-09 JP JP2008540343A patent/JP5240927B2/ja active Active
- 2006-11-09 NZ NZ568048A patent/NZ568048A/en not_active IP Right Cessation
- 2006-11-09 US US12/092,932 patent/US8178675B2/en active Active
- 2006-11-09 BR BRPI0618500-2A patent/BRPI0618500A2/pt not_active IP Right Cessation
- 2006-11-09 RU RU2008123000/15A patent/RU2420276C2/ru not_active IP Right Cessation
- 2006-11-09 CA CA2627363A patent/CA2627363C/en not_active Expired - Fee Related
- 2006-11-09 CN CNA2006800420285A patent/CN101304740A/zh active Pending
- 2006-11-09 EP EP06839799A patent/EP1948152B1/en not_active Not-in-force
2008
- 2008-04-15 NO NO20081821A patent/NO20081821L/no not_active Application Discontinuation
- 2008-04-17 IL IL190920A patent/IL190920A/en not_active IP Right Cessation
- 2008-04-18 ZA ZA200803440A patent/ZA200803440B/xx unknown
- 2008-05-30 KR KR1020087013156A patent/KR101344392B1/ko not_active Expired - Fee Related
2013
- 2013-02-08 JP JP2013023191A patent/JP2013082753A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
IL190920A (en)	2013-12-31
EP1948152A2 (en)	2008-07-30
RU2420276C2 (ru)	2011-06-10
RU2008123000A (ru)	2009-12-20
NZ568048A (en)	2011-08-26
US8178675B2 (en)	2012-05-15
HK1119577A1 (en)	2009-03-13
JP5240927B2 (ja)	2013-07-17
JP2013082753A (ja)	2013-05-09
IL190920A0 (en)	2009-09-22
EP1948152A4 (en)	2010-07-07
AU2006311266B2 (en)	2011-09-29
CN101304740A (zh)	2008-11-12
UA95613C2 (ru)	2011-08-25
US20090203793A1 (en)	2009-08-13
WO2007056771A2 (en)	2007-05-18
CA2627363A1 (en)	2007-05-18
KR20080074925A (ko)	2008-08-13
KR101344392B1 (ko)	2013-12-23
BRPI0618500A2 (pt)	2011-09-06
CN102743368A (zh)	2012-10-24
NO20081821L (no)	2008-07-30
EP1948152B1 (en)	2013-01-02
AU2006311266A1 (en)	2007-05-18
JP2009514987A (ja)	2009-04-09
WO2007056771A3 (en)	2007-11-22
CA2627363C (en)	2013-08-13

Publication	Publication Date	Title
IL190920A0 (en)	2009-09-22	Compounds for the treatment of metabolic disorders
EP1976377A4 (en)	2010-06-23	COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP1983972A4 (en)	2012-01-25	COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL195203A0 (en)	2009-08-03	Compounds for the treatment of metabolic disorders
IL208607A0 (en)	2010-12-30	Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL185016A0 (en)	2007-12-03	Compounds for the treatment of proliferative disorders
ZA200900734B (en)	2010-04-28	Combination treatment for metabolic disorders
ZA200806074B (en)	2009-05-27	Compounds for the treatment of inflammatory disorders
ZA200808178B (en)	2010-11-24	Imidazolothiazole compounds for the treatment of disease
IL169332A0 (en)	2007-07-04	Compounds for the treatment of metabolic disorders
ZA200805645B (en)	2009-09-30	Compounds for the treatment of metabolic disorders
IL195392A0 (en)	2009-08-03	Compounds for the treatment of metabolic disorders
IL192851A0 (en)	2009-02-11	Compounds for the treatment of metabolic disorders
GB0400802D0 (en)	2004-02-18	Compounds for the treatment of disease
EP2240024A4 (en)	2014-05-21	COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL192982A0 (en)	2009-02-11	Compounds for the treatment of metabolic disorders
GB0604782D0 (en)	2006-04-19	Use of substituted pyrimidinyl-2-piperazine compounds for the treatment of food related disorders
HK1122187A (en)	2009-05-15	Compounds for the treatment of metabolic disorders
HK1124246A (en)	2009-07-10	Compounds for the treatment of metabolic disorders
HK1120724A (en)	2009-04-09	Compounds for the treatment of metabolic disorders
HK1121935A (en)	2009-05-08	Compounds for the treatment of metabolic disorders
HK1121917A (en)	2009-05-08	Compounds for the treatment of metabolic disorders
HK1124486A (en)	2009-07-17	Compounds for the treatment of metabolic disorders
GB0604783D0 (en)	2006-04-19	Use of substituted oxime compounds for the treatment of food related disorders
HK1144778A (en)	2011-03-11	Compounds for the treatment of metabolic disorders